Eptacog beta for the management of patients with haemophilia A and B with inhibitors : A European perspective
© 2024 The Authors. Haemophilia published by John Wiley & Sons Ltd..
Eptacog beta (activated), a recombinant human factor VIIa (rFVIIa), was approved by the US Food and Drug Administration (FDA) in 2020 (SEVENFACT®, LFB & HEMA Biologics) and the European Medicines Agency (EMA) in 2022 (CEVENFACTA®, LFB). In Europe, eptacog beta is indicated for the treatment of bleeds and the prevention of bleeds during surgery or invasive procedures in adults and adolescents (≥12 years old) with congenital haemophilia A or B with high-titre inhibitors (≥5 BU) or with low-titre inhibitors who are expected to have a high anamnestic response to factor VIII or factor IX, or to be refractory to increased dosing of these factors. The efficacy and safety of eptacog beta were evaluated in three Phase III clinical studies, PERSEPT 1, 2 and 3. For the EMA filing dossier, the analysis of data from PERSEPT 1 and 2 differed from the analysis used to support the filing in the US. In this review, we summarise current data regarding the mode of action, clinical efficacy and safety of eptacog beta for the management of haemophilia A and B in patients with inhibitors from a European perspective. In addition to providing a valuable summary of the analyses of the clinical data for eptacog beta conducted for the EMA, our review summarises the potential differentiators for eptacog beta compared with other current bypassing agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Haemophilia : the official journal of the World Federation of Hemophilia - 30(2024), 2 vom: 15. März, Seite 257-266 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miesbach, Wolfgang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AC71R787OV |
|---|
| Anmerkungen: |
Date Completed 14.03.2024 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/hae.14944 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36806705X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36806705X | ||
| 003 | DE-627 | ||
| 005 | 20240314235032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240206s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hae.14944 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM36806705X | ||
| 035 | |a (NLM)38317441 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miesbach, Wolfgang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eptacog beta for the management of patients with haemophilia A and B with inhibitors |b A European perspective |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Haemophilia published by John Wiley & Sons Ltd. | ||
| 520 | |a Eptacog beta (activated), a recombinant human factor VIIa (rFVIIa), was approved by the US Food and Drug Administration (FDA) in 2020 (SEVENFACT®, LFB & HEMA Biologics) and the European Medicines Agency (EMA) in 2022 (CEVENFACTA®, LFB). In Europe, eptacog beta is indicated for the treatment of bleeds and the prevention of bleeds during surgery or invasive procedures in adults and adolescents (≥12 years old) with congenital haemophilia A or B with high-titre inhibitors (≥5 BU) or with low-titre inhibitors who are expected to have a high anamnestic response to factor VIII or factor IX, or to be refractory to increased dosing of these factors. The efficacy and safety of eptacog beta were evaluated in three Phase III clinical studies, PERSEPT 1, 2 and 3. For the EMA filing dossier, the analysis of data from PERSEPT 1 and 2 differed from the analysis used to support the filing in the US. In this review, we summarise current data regarding the mode of action, clinical efficacy and safety of eptacog beta for the management of haemophilia A and B in patients with inhibitors from a European perspective. In addition to providing a valuable summary of the analyses of the clinical data for eptacog beta conducted for the EMA, our review summarises the potential differentiators for eptacog beta compared with other current bypassing agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a eptacog alfa | |
| 650 | 4 | |a eptacog beta | |
| 650 | 4 | |a haemophilia A | |
| 650 | 4 | |a haemophilia B | |
| 650 | 4 | |a recombinant FVIIa | |
| 650 | 7 | |a recombinant FVIIa |2 NLM | |
| 650 | 7 | |a AC71R787OV |2 NLM | |
| 650 | 7 | |a Factor VIIa |2 NLM | |
| 650 | 7 | |a EC 3.4.21.21 |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 700 | 1 | |a Carcao, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Mahlangu, Johnny |e verfasserin |4 aut | |
| 700 | 1 | |a Dargaud, Yesim |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Yuste, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Hermans, Cédric |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haemophilia : the official journal of the World Federation of Hemophilia |d 1995 |g 30(2024), 2 vom: 15. März, Seite 257-266 |w (DE-627)NLM093860773 |x 1365-2516 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g day:15 |g month:03 |g pages:257-266 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hae.14944 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |b 15 |c 03 |h 257-266 | ||